Skip to main content

Table 1 Information of clinical trials of TCR-engineered T cells

From: Targeting cancers through TCR-peptide/MHC interactions

Antigen

Amino acid sequence of peptide

MHC molecule

Cancer

TCR used

Objective clincial response

Toxicity

Number of patients

References

MART-1

AAGIGILTV

HLA-A*0201

Melanoma

DMF4(human)

2/17 (12%)

None

17

103

MART-1

AAGIGILTV

HLA-A*0201

Melanoma

DMF5(human)

6/20 (30%)

On-target toxicity on normal melanocytes (Skin rash (14/20), Uveitis (11/20), Hearing impairment (10/20))

20

105

MART-1

EAAGIGILTV

HLA-A*0201

Metastatic melanoma

1D3HMCys(human)

9/13(69%)

Mild skin rash (3/13) serious adverse events(2/13) due to cytokine release syndrome

13

106

gp100

KTWGQYWQV

HLA-A*0201

Melanoma

gp100-154 (mouse)

3/16 (17%)

On-target toxicity on normal melanocytes (Skin rash (15/16), Uveitis (4/16), Hearing impairment (5/16))

16

103

NY-ESO-1

SLLMWITQC

HLA-A*0201

Melanoma

1G4-α95:LY(human)

5/11 (45%)

None

11

108

  

Synovial sarcoma

 

4/6 (67%)

 

6

 

CEA

IMIGVLVGV

HLA-A*0201

Metastatic colorectal cancer

L110F/S112T (mouse)

1/3(33%)

Severe inflammatory colitis (3/3) due to on-target toxicity in colon

3

113

MAGE-A3

KVAELVHFL

HLA-A*0201

Metastatic melanoma

MAGE-A3 A118T(mouse)

5/9 (56%)

Central nervous system toxicities (Necrotizing leukoencephalopathy and death (2/9), Parkinson-like symptoms (1/9), Aphasia (1/9)) due to recognition of MAGE-A12 in the brain

7

114

  

Synovial sarcoma

   

1

 
  

Esophageal cancer

   

1

 

MAGE-A3

EVDPIGHLY

HLA-A*01

Ulcerated melanoma

MAGE-A3a3a (human)

NA

Cardiac toxicity and death (2/2) due to cross-recognition of an unrelated epitope from Titin (TTN)

1

119

  

Myeloma

   

1

 

MAGE-A4

NYKRCFPVI

HLA-A*2402

Esophageal cancer

MS-bPa(human)

0/10 (0%)

None

10

115

NY-ESO-1

SLLMWITQC

HLA-A*0201

Synovial cell sarcoma

1G4-α95:LY (human)

11/18 (61%)

None

18

116

  

Melanoma

 

11/20 (55%)

 

20

 

NY-ESO-1

SLLMWITQC

HLA-A*0201

Multiple myeloma

NY-ESOc259 (human)

16/20 (80%)

None

20

117

WT1

CMTWNQMNL

HLA-A*2402

AML and MDS

pMS3-WT1-siTCR(human)

2/8 (25%)

None

8

118